Clinical-stage biopharmaceutical company Timber Pharmaceuticals, Inc. (TMBR) develops and commercializes various treatments for orphan dermatologic diseases.
On August 11, 2022, John Koconis, TMBR’s Chairman and CEO, said, “During the second quarter, Timber achieved several significant milestones for our lead asset, TMB-001. These include the launch and enrollment of the first patients for the pivotal Phase 3 ASCEND study, and the receipt of Breakthrough Therapy designation from the FDA in May and Fast Track designation in April.”
